Navigation Links
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients

off" time (i.e., time when normal Parkinson's medication was ineffective and symptoms were troubling to the patient) and a doubling of good quality "on" time without dyskinesias (i.e., time when a patient is functioning well) according to self-reported diaries.

This Phase 1 clinical trial was partially supported by a grant from The Michael J. Fox Foundation for Parkinson's Research. Based on the results of the Phase 1 study, the Foundation has provided a $1.9 million grant, which will provide partial funding for Ceregene's ongoing Phase 2 trial.

"We are pleased with the results of this early study which suggests that the majority of patients treated with CERE-120 may have exhibited significant and stable improvement for a full year after receiving a single administration of CERE-120," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "Each of our products, much like CERE-120, is aimed at unmet neurodegenerative diseases including Parkinson's disease, Alzheimer's disease and Amyotrophic Lateral Sclerosis (AML or Lou Gehrig's disease) with the goal of not only improving the symptoms but also preventing progression of the disease."

"Through stereotactic surgery, we are able to administer CERE-120 in a highly targeted fashion to one area of the brain that Parkinson's disease affects, and we were able to do this safely," stated Dr. Starr.

"Given the encouraging data from the Phase 1 trial of CERE-120 in Parkinson's disease, we are conducting a follow-on Phase 2 clinical trial that is currently enrolling patients at nine clinical trial sites in the United States," said Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer. "The data from the Phase 1 trial are reflective of the impressive results we gathered from preclinical studies, which demonstrated the ability of CERE-120 to stimulate the survival and improve the function of key neuronal c
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical Call ... triage and nurse advice lines, announces its newly ... physician, nursing and administrative leaders, provides clinical expertise ... and cost-effective services for hospital clients, physician clients ... healthcare system evolves, it,s imperative to continuously advance ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... the region,s premier provider of diagnostic imaging services, is ... Hospital Council of Western Pennsylvania,s newest business partner. ... the expertise of a large, highly-skilled team of imaging ... area. By partnering with FRG, community hospitals are able ...
... OAKS, Calif., Oct. 18 Amgen (Nasdaq: ... Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and ... of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) ... Administration,s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC). ...
Cached Medicine Technology:Hospital Council of Western Pennsylvania Announces Foundation Radiology Group as Newest Partner 2Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 2Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 3Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 4Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 5Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 6Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 7Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 8
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... a federal multidistrict litigation underway in U.S. District Court, ... Liebhard LLP reports. According to a Case Management ... procedures that govern the filing of contested motions in ... for filing those motions. (In re: Actos Product Liability ...
(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... digestive problems, ranging from irritable bowel syndrome (IBS) ... problems are among the most long-lasting, embarrassing, frustrating ... natural foods for digestive health have ... While there are many factors contributing to digestive ...
(Date:5/25/2013)... UAE (PRWEB) May 25, 2013 Dr. ... LASIK surgery clinic in Dubai, has announced his practice’s ... laser is the only FDA-cleared femtosecond laser proven with ... the safety and precision of LASIK. , “We are ... iFS Advanced Femtosecond Laser at our Dubai LASIK practice,” ...
(Date:5/25/2013)... May 25, 2013 Prairie Living ... is hosting an American Red Cross Blood Drive from ... The community, which is located at 955 Villa Ct. ... including those on Medicaid, who need some help to ... of Life," says Andrea Arview Frey, Director of Marketing ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
... , TUESDAY, Oct. 11 (HealthDay News) -- Environmental pollutants ... hardening of the arteries (atherosclerosis), according to a new ... cardiovascular diseases, which are the most common cause of ... University in Sweden. They measured levels of persistent ...
... have identified cells and signaling molecules that trigger the ... his colleagues report October 10, 2011, online in the ... lung tissue in mice induces smooth muscle cells surrounding ... growth factor 10 (FGF10), which induces surviving epithelial cells ...
... Reserve University School of Medicine and the Case ... receipt of a highly competitive $5.4 million grant ... esophageal adenocarcinoma. This five-year award from the National ... Research Network (BETRNet), which consists of multiple centers ...
... medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and ... tract symptoms among men according to a Kaiser ... Internal Medicine . This study demonstrates an ... drugs and LUTS among men enrolled in the ...
... Society for Radiation Oncology (ASTRO), the Association of Residents ... the 2011 Educator of the Year Award. , ARRO ... recognize outstanding teachers and mentors of radiation oncology residents. ... opportunity to select one faculty member from their program ...
... as herbal supplements have become increasingly popular in the ... chronic pain. However, many of these products can have ... medications prescribed during and after surgery, according to a ... American Academy of Orthopaedic Surgeons (JAAOS). , ...
Cached Medicine News:Health News:Environmental Toxins Linked to Hardening of Arteries 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 3Health News:Common medications can contribute to lower urinary tract symptoms in men 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 3
... PDC Smart™ Labels have a direct ... Texas Instruments Tag-it™ HF-I transponder. When ... codes, text and other graphics may ... variable data is programmed to the ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... SURGICHIP™ is a patent pending ... technology embedded in a smart label ... to prevent wrong-patient, wrong-site, wrong-procedure surgery. ... developed by an orthopedic surgeon with ...
... are carefully crafted with the highest ... SATO Techno THERM RFID labels are ... optimum performance in your SATO printer ... are available in HF and UHF ...
Medicine Products: